



HOSPITAL AUTHORITY DRUG FORMULARY
(v18.2 - w.e.f. 8 Oct 2022)
new drugs listed highlighted in "yellow" color

- (1) The drugs may either be listed as generic or proprietary names, where appropriate. Brand names listed serve as reference only, they do not necessarily indicate the availability of that particular brand.
- (2) Some drugs may appear in more than one category due to different formulations and/or indications.
- (3) The "Special" drugs will be prescribed as clinically indicated based on the specified indications.
- (4) Based on operational logistics and needs, individual cluster/hospital may only stock part of the drugs listed in the HA Drug Formulary.

I	SPECIAL PROGRAMMES FOR USE OF DRUGS ON INDIVIDUAL PATIENTS 個別病人特別用藥計劃
	AGALSIDASE ALFA AGALSIDASE BETA ALGLUCOSIDASE ALFA DINUTUXIMAB BETA ECULIZUMAB ELOSULFASE ALFA GALSULFASE IDURSULFASE IMIGLUCERASE LARONIDASE NUSINERSEN TAFAMIDIS TAFAMIDIS MEGLUMINE TISAGENLECLEUCEL